Connor, Clark & Lunn Investment Management (CC&L)
OVID icon

Connor, Clark & Lunn Investment Management (CC&L)’s Ovid Therapeutics OVID Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,431
Closed -$13.5K – 1574
2024
Q3 		$13.5K Buy
+11,431
New +$11.9K ﹤0.01% 1397
2024
Q2 		– Sell
-84,233
Closed -$257K – 1601
2024
Q1 		$257K Buy
84,233
+3,058
+4% +$10.2K ﹤0.01% 1321
2023
Q4 		$261K Buy
81,175
+2
+0% +$7 ﹤0.01% 1205
2023
Q3 		$312K Buy
81,173
+11,926
+17% +$42.9K ﹤0.01% 1128
2023
Q2 		$227K Buy
69,247
+38,389
+124% +$130K ﹤0.01% 1163
2023
Q1 		$79.6K Sell
30,858
-9,062
-23% -$21.5K ﹤0.01% 1170
2022
Q4 		$74.3K Sell
39,920
-2,665
-6% -$4.54K ﹤0.01% 1130
2022
Q3 		$78K Buy
42,585
+5,837
+16% +$12.2K ﹤0.01% 1049
2022
Q2 		$79K Sell
36,748
-50,140
-58% -$121K ﹤0.01% 998
2022
Q1 		$273K Sell
86,888
-32,685
-27% -$103K ﹤0.01% 893
2021
Q4 		$384K Sell
119,573
-80,000
-40% -$274K ﹤0.01% 852
2021
Q3 		$671K Sell
199,573
-57,991
-23% -$211K ﹤0.01% 713
2021
Q2 		$1.01M Buy
257,564
+5,800
+2% +$22.9K 0.01% 671
2021
Q1 		$1.01M Buy
251,764
+19,705
+8% +$65.4K 0.01% 693
2020
Q4 		$536K Buy
232,059
+82,070
+55% +$383K ﹤0.01% 715
2020
Q3 		$861K Sell
149,989
-39,978
-21% -$268K 0.01% 651
2020
Q2 		$1.4M Buy
189,967
+31,380
+20% +$147K 0.01% 534
2020
Q1 		$473K Buy
+158,587
New +$534K ﹤0.01% 704

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s OVID Position: Q4 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Ovid Therapeutics (OVID) in Q4 2024, closing a stake of 11,431 shares — an estimated $13.5K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in OVID in Q1 2020 and held it in 18 quarters. The position peaked at $1.4M in Q2 2020. 82 funds tracked by Wall St. Rank hold OVID as of Q4 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Ovid Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 11,431 Ovid Therapeutics shares in Q4 2024, an estimated $13.5K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Ovid Therapeutics in Q1 2020 and held it in 18 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Ovid Therapeutics position peaked at $1.4M in Q2 2020.
  • 82 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2024, filed 10 Feb 2025.